WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, is one of several companies spotlighted in the August 2012 issue of Drug Discovery News in a special report about regenerative medicine.
